Psilocybin study enrolls clinicians with… blues
This is the first study of the therapy’s potential benefit with clinicians, and the University of Washington School of Medicine is the sole trial site.
Dr. Anthony Back, the trial’s lead investigator. suggested that psilocybin uniquely enables psychological exploration. “It makes your brain more plastic and your beliefs and desires less rigid. It can allow people to break up habitual cycles of thoughts and beliefs” that might cause their sadness and depression.